Abstract:TP53 mutations are the most common molecular alterations in non-small cell lung cancer (NSCLC), but prognostic role of these mutations remains elusive. The aim of this study was to analyze the clinical and molecular characteristics of TP53 mutated NSCLC patients and to evaluate a novel approach called evolutionary action (EAp53) to stratify them into high-risk or low-risk groups. 85 advanced NSCLC patients were enrolled. Variations of TP53 and other oncogenic drivers in NSCLC were identified by next-generation sequencing. EAp53 are available at http://mammoth.bcm.tmc.edu/EAp53/. Overall, 77 patients (90.6%) exhibited at least one genetic alteration. TP53 mutations were detected in 51 patients (60.0%) mainly in exons 4, 5, 6, 7, and 8. Notably, TP53 mutations were not observed in exon 4 when they coexisted with EGFR mutations. Mutant allele frequencies (MAFs) of EGFR sensitizing mutations (exon 19 deletion or L858R) were significantly higher than those of other EGFR mutations in patients harboring TP53 mutations (p = 0.012). Among TP53 mutated patients, 39.2% of them carried TP53 truncating mutations (nonsense, splice site, or frameshift), which were correlated with female gender and smokers (p = 0.026 and p = 0.024, respectively), and were potentially associated with young patients (p = 0.078), and were more common in non-DNA-binding domain of TP53 (p = 0.033). Additionally, overall survival time of 37 patients were collected, and patients with high-risk mutations stratified by EAp53 had a significantly worse OS compared to others (HR 23.15; 95% CI 4.30-124.50; p <0.001). This study is of great significance in understanding the population characteristics of TP53 mutated NSCLC patients. Furthermore, the data also indicates that evolutionary high risk TP53 mutations can identify a subset of patients with poor prognosis, suggesting that EAp53 is a novel approach and may be useful in clinical prognosis of NSCLC patients with TP53 mutations.

Analysis of the relationship between p53 gene mutation and clinical pathophysiological characteristics of primary non-small cell lung cancer

Effects of plasma p53 gene mutation in the development and prognosis of non-small cell lung cancer

Study on relationship between mutant p53 and multidrug resistance gene 1 in gastric cancer

Relationship Between P21,p53 Expression and Single Nucleotide Polymorphism with Hepatocellular Carcinoma

Relationship between expression of multidrug resistance protein,PCNA and p53 and its significance in patients with non-small cell lung cancer

The Relationship Between P53 Gene Mutations and Clinicopathological Features in Glioma

Analysis of p53 exon 4-8 gene mutations in human esophageal cancer tissue and nearby non-cancerous tissue

Detection of p53 gene mutation in exhaled breath condensate of patients with non-small cell lung cancer

Clinical Value of P_53 Gene Mutation in Bladder Cancer

The Clinical Significance of Detection of P53 Gene Mutation in Patients with Lung Cancer

p53 gene mutation and numb expression in colorectal cancer and its clinical significance

Expression and Significance of P51 Gene in Breast Cancer

[Detection of P53 Mutation Using PCR-SSCP Silver Staining Method].

[Human Papillomavirus, Human Cytomegalovirus and P53 Gene in Cervical Carcinoma].

[Clinical Significance of Mutant P53 Protein Expression in Lung Adenocarcinoma].

P53 Protein Expression Levels in Stage I Breast Cancer and Its Relationship to Clinico - Pathologic Parameters

Clinical Biology Value of P53 Overexpression in Chinese Breast Cancer by Meta Analysis

Correlation Between the Expression of P53v, P16 Gene and DNA Content in the Tumor Tissue of Patients with Lung Cancer and Its Significance

P53 Gene Mutations in Surgical Margins with Esophageal Squamous Cell Carcinoma

The clinical features and prognostic implications of the co-mutated TP53 gene in advanced non-small cell lung cancer

P2.01-45 Clinico-Molecular Characteristics and Prognostic Outcomes of TP53 Mutated Patients with Advanced Non-Small Cell Lung Cancer